This page contains a Flash digital edition of a book.
industry focus.


Vindon participates in development of new Stem Cell Collection Service, Oristem®


Vindon Healthcare is pleased to announce the involvement of Vindon Cryobank Ltd, its wholly owned subsidiary, in the Oristem® stem cell bank, a significant new medical breakthrough involving the collection and storage of stem cells from adults.


Oristem® ’s service has been developed through a


partnership between Vindon, Pharmacells Limited and Altrika. Pharmacells has licensed a new, patented method of harvesting, isolating and storing stem cells derived from an adult’s blood. Altrika is a cell therapeutics company specialising in the fields of wound treatment and skin regeneration.


As one of the few commercial organisations with experience of both cell processing and advanced therapies, Vindon is a recognised leader in temperature and humidity controlled storage.


Vindon’s state of the art Cryobank for the storage of human tissue and cells will provide secure storage and support to both Altrika and Oristem in this new and exciting field. Vindon’s involvement in this key step of the Oristem programme will ensure that the samples received from clients are handled with the greatest care and stored to the level required for future use in treatment.


Oristem®


“ Vindon is pleased to be collaborating with Pharmacells and Altrika to deliver Oristem’s service to the UK market. Vindon is particularly committed to providing storage services in the fields of regenerative medicine and cell therapy and to be able to offer the benefits of this exciting field to a much broader range of people will help to extend its availability, and ultimately improve the nation’s health.”


Patrick Jackson, Director of Vindon


Previous forms of stem cell extraction had been confined to neo-natal stem cells taken from umbilical cords and immediately stored, or more invasive sources such as fat tissue or bone marrow. The concept of stem cells from adult blood is very new and represents an important development in the possible treatment of illnesses that adults may contract in the future.


offers a customised stem cell collection system that enables adults to be visited at home for blood samples to be taken. These samples are then developed into a personalised stem cell kit, which can be frozen and stored for future use, if and when a new stem cell based treatment for a particular disease has been developed. It thus represents a form of medical investment on the part of individuals wishing to maximise their chances of recovery from future illnesses.


Stem cells are being used in many scientific projects around the world and research is being performed into a wide variety of diseases and conditions ranging from Alzheimer’s, Parkinson’s, Multiple Sclerosis, Diabetes, various cancers and infectious diseases through to repair of corneal damage and soft skin, cartilage and tissues. Several stem cell based products are already in the market, with several more at clinical trial stage and expected to be available soon.


Patrick Jackson


www.regener8.ac.uk


21


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36